Literature DB >> 11333159

Allopurinol enhances adenine nucleotide levels and improves myocardial function in isolated hypoxic rat heart.

S Y Khatib1, H Farah, F El-Migdadi.   

Abstract

Allopurinol, a competitive inhibitor of xanthine oxidase, was found to have a protective effect on ischemic myocardium. Its mechanism of action is still controversial. We used Langendorff isolated rat heart preparation to test the hypothesis that allopurinol could maintain a level of the adenine nucleotide pool (ATP, ADP, and AMP) that would protect and improve the functional activity of the heart during a period of hypoxia. Hearts were initially perfused for 30 min until steady state was attained. This was followed by 20 min of experimental perfusion divided into 5 min of control perfusion followed by 15 min of hypoxic perfusion with or without allopurinol in the perfusate. Hearts were quick-frozen and enzymatically analyzed for adenine nucleotides and creatine phosphate at the end of the hypoxic period. Left ventricular pressure, heart rate, and coronary flow were measured in all preparations. Allopurinol (0.1 mM) treated hearts had greater levels of ATP (12.3 +/- 0.8 vs. 9.3 +/- 0.8 micromol/g dry weight; p < 0.01). This improvement occurred in the presence as well as the absence of glucose. Total adenine nucleotides improved from 17 +/- 1 to 20.3 +/- 2.4 micromol/g dry weight (p < 0.01). This improvement also occurred in the presence as well as in the absence of glucose in the perfusate. It also improved cell energy state significantly in the presence as well as the absence of glucose. There was insignificant change in creatine phosphate. Allopurinol improved left ventricular pressure from 38 +/- 7% to 55 +/- 9% (p < 0.002) in the presence of glucose and from 8 +/- 3% to 27 +/- 6.3% (p < 0.001) in the absence of glucose. Coronary flow improved from 110 +/- 5% to 120 +/- 8% (p < 0.04) in the presence of glucose. These results support the suggestion that allopurinol at 0.1 mM exerts its protective effect on rat heart during hypoxia by enhancing the adenine nucleotide pool.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333159     DOI: 10.1023/a:1010264216357

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  7 in total

Review 1.  Stable angina pectoris: antianginal therapies and future directions.

Authors:  Bernard R Chaitman; Abhay A Laddu
Journal:  Nat Rev Cardiol       Date:  2011-08-30       Impact factor: 32.419

Review 2.  Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care.

Authors:  Hyon K Choi; Natalie McCormick; Chio Yokose
Journal:  Nat Rev Rheumatol       Date:  2021-12-17       Impact factor: 32.286

3.  Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial.

Authors:  Awsan Noman; Donald S C Ang; Simon Ogston; Chim C Lang; Allan D Struthers
Journal:  Lancet       Date:  2010-06-09       Impact factor: 79.321

4.  Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP.

Authors:  Todd A Johnson; H A Jinnah; Naoyuki Kamatani
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

5.  Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury.

Authors:  Takashi Tani; Ken Okamoto; Megumi Fujiwara; Akira Katayama; Shuichi Tsuruoka
Journal:  Mol Med       Date:  2019-08-22       Impact factor: 6.354

6.  Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.

Authors:  Isla S Mackenzie; Ian Ford; Andrew Walker; Chris Hawkey; Alan Begg; Anthony Avery; Jaspal Taggar; Li Wei; Allan D Struthers; Thomas M MacDonald
Journal:  BMJ Open       Date:  2016-09-08       Impact factor: 2.692

7.  A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting.

Authors:  Tejas P Singh; Tristan Skalina; Daniel Nour; Aarya Murali; Sean Morrison; Joseph V Moxon; Jonathan Golledge
Journal:  BMC Cardiovasc Disord       Date:  2018-07-11       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.